Starling Oncology, Inc.
STLN- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Starling Oncology, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +20 vs. Q3 2021
- Shares held
- 21.1M
- +20.9M (+8,265.6%) vs. Q3 2021
- Total value
- $199.9M
- +$197.4M (+7,882.5%) vs. Q3 2021
- New holders
- 21
- 0 more added
- Sold out
- 1
- 0 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STLN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $217.6M |
| Q1 2026 | 115 | $118.9M |
| Q4 2025 | 117 | $137.1M |
| Q3 2025 | 108 | $121.0M |
| Q2 2025 | 79 | $65.5M |
| Q1 2025 | 43 | $19.4M |
| Q4 2024 | 31 | $4.61M |
| Q3 2024 | 34 | $6.73M |
| Q2 2024 | 39 | $8.60M |
| Q1 2024 | 47 | $27.2M |
| Q4 2023 | 45 | $37.6M |
| Q3 2023 | 36 | $21.2M |
| Q2 2023 | 38 | $7.66M |
| Q1 2023 | 39 | $14.9M |
| Q4 2022 | 40 | $38.7M |
| Q3 2022 | 39 | $108.4M |
| Q2 2022 | 36 | $110.9M |
| Q1 2022 | 29 | $159.0M |
| Q4 2021 | 21 | $199.9M |
| Q3 2021 | 1 | $2.50M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Starling Oncology, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,000,000 | $111.2M | 0.01% | +12,000,000 | New |
| Deerfield Management Company, L.P. (Series C) | 3,296,107 | $32.1M | 0.68% | +3,296,107 | New |
| Redmile Group, LLC | 2,500,000 | $24.4M | 0.55% | +2,500,000 | New |
| Velan Capital Investment Management LP | 600,000 | $5.85M | 4.89% | +600,000 | New |
| Parian Global Management LP | 466,676 | $4.55M | 4.12% | +466,676 | New |
| Vanguard Group Inc | 442,344 | $4.31M | 0.00% | +442,344 | New |
| Hongkou Capital LP | 400,000 | $3.90M | 3.86% | +400,000 | New |
| Alpine Global Management, LLC | 384,988 | $3.75M | 0.56% | +384,988 | New |
| Saba Capital Management, L.P. | 400,000 | $3.73M | 0.08% | +400,000 | New |
| Empery Asset Management, LP | 200,000 | $1.95M | 4.07% | +200,000 | New |
| CVI Holdings, LLC | 200,000 | $1.95M | 0.13% | +200,000 | New |
| Goldman Sachs Group Inc | 116,098 | $1.13M | 0.00% | +116,098 | New |
| Citadel Advisors LLC | 39,561 | $386.0K | 0.00% | +39,561 | New |
| ExodusPoint Capital Management, LP | 30,700 | $299.0K | 0.00% | +30,700 | New |
| Qube Research & Technologies Ltd | 18,688 | $182.0K | 0.00% | +18,688 | New |
| Geode Capital Management, LLC | 11,147 | $108.0K | 0.00% | +11,147 | New |
| Penserra Capital Management LLC | 5,038 | $49.0K | 0.00% | +5,038 | New |
| JPMorgan Chase & Co | 3,800 | $37.0K | 0.00% | +3,800 | New |
| UBS Group AG | 1,859 | $18.0K | 0.00% | +1,859 | New |
| Morgan Stanley | 932 | $9.00K | 0.00% | +932 | New |
| Tower Research Capital LLC (TRC) | 200 | $2.00K | 0.00% | +200 | New |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −252,439−100.0% | Sold out |